Prices being paid to both in-license compounds and acquire companies with promising drug candidates have skyrocketed in the past year, leaving many pharmaceutical and biotech companies wondering whether theyll ever see an adequate return on investment. As many companies face the patent expiration of their blockbuster products, their need to fill their drug development pipeline becomes all the more acute, placing emerging biotechs in a bargaining position of greater strength than ever before.

BioNetwork 2007, October 10-12 at the Ritz Carlton in Laguna Niguel, CA, will explore how these trends are affecting deal-making and the process of establishing strategic partnerships, with VPs of Business Development, Licensing, and Alliance Management from top companies offering their insights. Most importantly, BioNetwork provides a venue for you to meet potential partners and hold quality discussions -- free of the distractions accompanying larger events.

Weblink - BioNetwork 2007